The Claim

In obese mice on a high-fat diet, 8 weeks of empagliflozin treatment reduced liver fat accumulation by 40% and lowered plasma triglycerides and cholesterol, accompanied by increased fatty acid oxidation and reduced expression of lipogenic genes, resulting in attenuation of hepatic steatosis.

Source: Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
16score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In obese mice fed a high-fat diet, empagliflozin treatment for 8 weeks decreased liver fat by 40%, reduced blood triglycerides and cholesterol, increased fatty acid oxidation, and decreased the activity of genes that produce fat, leading to less fatty liver disease.

See the scientific wording

In obese mice on a high-fat diet, empagliflozin treatment for 8 weeks reduced liver fat accumulation by 40% and lowered plasma triglycerides and cholesterol, associated with increased fatty acid oxidation and reduced lipogenic gene expression, indicating attenuation of hepatic steatosis.

Why this might work

When the kidneys excrete more sugar due to empagliflozin, the body switches from using sugar to burning fat for energy. This forces the liver to break down its stored fat and stop making new fat. Fat-burning cells in fat tissue become more active, releasing signals that tell the liver to burn even more fat. At the same time, immune cells in fat and liver switch to a repair mode, reducing inflammation and improving how the liver responds to insulin, which further stops fat buildup.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

    In obese mice, a diabetes drug called empagliflozin helped reduce fat in the liver and made the body burn more fat instead of storing it, which is exactly what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.